Clinical Trials Logo

Filter by:
NCT ID: NCT01418352 Completed - Tourette's Disorder Clinical Trials

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Start date: August 2, 2011
Phase: Phase 3
Study type: Interventional

The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.

NCT ID: NCT01416441 Completed - Tourette's Disorder Clinical Trials

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Start date: October 19, 2011
Phase: Phase 3
Study type: Interventional

The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.

NCT ID: NCT01412957 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene homolog) metastatic colorectal cancer.

NCT ID: NCT01412424 Completed - Acromegaly Clinical Trials

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Start date: March 2012
Phase: Phase 3
Study type: Interventional

MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.

NCT ID: NCT01412060 Completed - Schizophrenia Clinical Trials

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Start date: September 27, 2011
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.

NCT ID: NCT01408576 Completed - Clinical trials for Systemic Lupus Erythematosus

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

EMBODY4
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)

NCT ID: NCT01405196 Completed - Clinical trials for Lupus Erythematosus, Systemic

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

BUTTERFLY
Start date: December 2011
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. The study will evaluate secondary and exploratory measures as well.

NCT ID: NCT01400867 Completed - Clinical trials for Infections, Pediatrics

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Start date: December 2011
Phase: Phase 2/Phase 3
Study type: Interventional

This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil in children with skin infections receiving antibiotic therapy in the hospital.

NCT ID: NCT01397786 Completed - Schizophrenia Clinical Trials

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

ZENITH
Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.

NCT ID: NCT01396421 Completed - Acute Schizophrenia Clinical Trials

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

VECTOR
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.